: dr. richard klausner, director of grail, a company developing a blood test for cancer, known as a liquid biopsy. >> somebody with no symptoms could get their blood drawn? >> exactly. >> reporter: you could determine if they have cancer. >> the holy grail. >> reporter: the idea hold great promise. klausner says proving it works will take time. >> we just don't have the clinical data yet. we have to get it. >> reporter: there is a lot of incentive, the liquid biopsy market is expected to be worth $22 billion by 2020. another company after a piece of it, san diego based pathway genomics. pathway raised $40 million in its last round of fund-raising. >> like the most amazing thing. >> reporter: and raised its profiles when one genetic test was featured on "keeping up with the kardashians." >> hi, how are you. >> mitch mulinex. with pathway genomics. nice to meet you. >> reporter: what caught our attention, the test launched in >> introducing pathway genomics revolutionary test cancer intercept detect and monitor. >> reporter: available by physician order for as little as $299, pathway'
Fetching more results